Monalizumab
Monalizumab is a monoclonal antibody used in cancer immunotherapy.
| Drug Information | |||
|---|---|---|---|
| Image | |||
| Identifiers
ATC Code PubChem DrugBank ChemSpider ID UNII KEGG ChEBI ChEMBL IUPAC Name |
Chemical Data
C H N O Molecular Weight | ||
Monalizumab is a monoclonal antibody that targets the NKG2A receptor, which is an inhibitory receptor found on natural killer cells and some T cells. It is being investigated for its potential use in cancer immunotherapy.
Mechanism of Action[edit | edit source]
Monalizumab works by blocking the interaction between NKG2A and its ligand, HLA-E. NKG2A is an inhibitory receptor that, when engaged, can dampen the immune response. By inhibiting this interaction, monalizumab can enhance the activity of natural killer cells and T cells, promoting a stronger immune response against cancer cells.
Clinical Development[edit | edit source]
Monalizumab is currently undergoing clinical trials to evaluate its efficacy and safety in treating various types of cancer, including head and neck cancer, ovarian cancer, and colorectal cancer. Early studies have shown promise, with some patients experiencing tumor shrinkage and improved survival rates.
Potential Benefits[edit | edit source]
The use of monalizumab in cancer therapy offers several potential benefits:
- Enhanced Immune Response: By blocking the inhibitory signals, monalizumab can potentiate the body's natural immune response against tumors.
- Combination Therapy: Monalizumab is being studied in combination with other immunotherapies, such as PD-1 inhibitors, to assess synergistic effects.
- Broad Applicability: The mechanism of action suggests that monalizumab could be effective against a wide range of cancers.
Side Effects[edit | edit source]
As with many immunotherapies, monalizumab can cause immune-related side effects. These may include:
- Fatigue
- Fever
- Skin rash
- Gastrointestinal disturbances
Patients receiving monalizumab are closely monitored for these and other potential adverse effects.
Research and Development[edit | edit source]
Monalizumab is being developed by Innate Pharma in collaboration with AstraZeneca. The ongoing research aims to better understand the optimal use of monalizumab in cancer treatment and to identify which patient populations may benefit the most.
Also see[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
